PPM 2000 And Guardly Announce Improved Real-time Data Systems Integration For Monitoring And Responding To Active Threats
Joint whitepaper on how smartphones enhance real-time threat assessment is now available
PPM 2000 and Guardly today announced an updated integration between Perspective V.4.0 by PPM™ and Guardly Command™ that provides command center operators with more actionable data in the first few seconds of an emergency event and real-time communication tools that enhance information gathering from emergency callers by operators. This improved situational awareness allows operators to make key decisions faster and more effectively, better manage resources and assets, and ultimately improve business resiliency and risk mitigation for their customers.
I'm a textSuperior Results in Foamix’s Minocycline Foam Clinical Study. 71% Reduction in Inflammatory Lesions in 6 weeks.
Jun 11, 2013
Foamix, a clinical stage specialty pharma company, has announced today the successful completion of its Minocycline foam Phase II clinical trial. The drug was shown to be highly effective in this double blind, dose ranging, placebo controlled study of 150 moderate to severe acne patients. Once daily treatment of Minocycline Foam 4% exhibited an average 71% reduction in inflammatory lesions after 6 weeks with a respective reduction of 55% in non-inflammatory lesions. These extremely positive Minocycline Foam results follow on from those of the Impetigo Study announced in March last year.RichText.
EarlySense Closes $15 Million E Financing Round Led by Pitango Venture Capita
November 12, 2012
Waltham, MA, November 12, 2012 — EarlySense Ltd., the market leader in proactive patient care solutions, announced today that it has completed a $15 million E financing round led by Pitango Venture Capital. Existing investors that participated include JK&B, ProSeed VC Fund, Docor International Management and Bridge Investment Fund. EarlySense plans to use the financing to accelerate sales, further develop its contact-free, patient monitoring solutions, and to expand clinical research.
HOLLAND, MICHIGAN (September 5, 2012): Code Blue Corporation today announced it has entered into partnership with Canadian-based Guardly Corp., a company that has an established mobile safety and security platform and set of mobile applications for commercial public safety uses.
The partnership will allow Code Blue, already an industry leader in manufacturing emergency communication devices and help points, to enhance the incident initiation and response solutions it currently provides to colleges, corporations and municipalities around the world. Code Blue will become the first provider of blue light emergency phones to include mobile applications into its integrated suite of products that can be used to report emergencies and engage in two-way communication with emergency response personnel.
Foamix’s Minocycline Foam – 100% Effective in Impetigo Phase II Clinical Trial with No Side Effects. 80% Improved Significantly After 3 Days of Treatment
March 14, 2012
Foamix, a clinical stage specialty pharmaceutical company, announced today the successful completion of the Phase II clinical trial of Minocycline foam in Impetigo patients. Minocycline Foam has shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA).
EarlySense Raises $7 Million in D Round Led by JK & B
October 20, 2010
Ramat Gan, Israel, October 20, 2010 — EarlySense, developer of the EverOn® patient supervision system for hospital and post acute care, announced today that the company has closed an additional US$7 million D financing round led by JK & B. Pitango and other existing investors also participated. This round augments the previous C round closed on June, 2010 and brings the total amount raised in 2010 to $20M. Due to favorable market responses, the financing will be used to accelerate the global market launch of the EverOn system. To date, EarlySense has raised US$31 million.
EarlySense Raises $13 Million from Pitango and Current Investors
June 3, 2010
Ramat Gan, Israel, June 3, 2010 — EarlySense, developer of the Everon patient supervision system for hospital and post acute care, announced today that the company has closed a US$13 million third financing round led by Pitango Venture Capital. Current shareholders Etgar Challenge Fund, Proseed VC Fund, Docor International Management, Noaber, and Bridge Investment Fund also participated. To date, EarlySense has raised about US$24 million in three rounds.
Foamix LTD. And Therapeutics INC. ENTER INTO JOINT VENTURE TO DEVELOP NEW PRESCRIPTION FOAMS FOR Inflammatory Skin Diseases - Will Target Over 20 Mmillion Psoriasis And Atopic Dermatitis Patients
March 3, 2010
Foamix Ltd., (Foamix), a leading developer of topical foams for dermatological and gynecological use, and Therapeutics Inc. (TI), an innovative drug development company, announced today a joint venture that will focus on developing new prescription medicated foam formulations and demonstrating their safety and efficacy.